SV Health Investors is a specialist healthcare venture capital and growth equity firm founded in 1993, investing across biotechnology, medical devices, dementia, and healthcare technology. With offices in Boston and London, the firm creates and builds companies that advance science and transform healthcare across stages from early-stage to growth equity.
32% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $66.6M (across 70 rounds with reported amounts).
Portfolio
61
Fund Size
—
Top Stage
Series B
Last 12 Mo
8
Team
Greg Madden
Managing Partner
Michael Balmuth
Managing Partner
Paul LaViolette
Managing Partner
Christian Jung
Partner
Laurence Barker
Partner
Luke Johnson
Operating Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
77 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mestag Therapeutics Limited | Series B | $40M | Mar 2026 |
| TTRexBio, Inc. | Series C | $50M | Jan 2026 |
 Health Payment Systems | Growth | $33M | Jan 2026 |
 Trex Bio | Unknown | $50M | Jan 2026 |
 PayMedix | Growth | $33M | Jan 2026 |
 Artios Pharma | Series D | $115M | Nov 2025 |
| AArtios | Series D | $115M | Nov 2025 |
 Dualitas Therapeutics | Series A | $65M | Sep 2025 |
| TTherini Bio | Series A | $39M | May 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
| IImbria | Unknown | $57.5M | Apr 2025 |
 Draig Therapeutics | Series A | $140M | Jan 2025 |
| IImbria | Series B | $57.5M | Jan 2025 |
| EEnara Bio, Ltd. | Series B | $32.5M | Oct 2024 |
 SpectraWAVE | Series B | $50M | Sep 2024 |
 CSA Medical | Series D | $53M | Sep 2024 |
| CCsa Medical Inc | Series D | $53M | Sep 2024 |
| BBrixton Biosciences | Series B | $33M | May 2024 |
 CarePredict | Series A | $29M | Jul 2023 |
| HHealth Payment Systems, Inc. (HPS)/PayMedix | Growth | $25M | Jan 2023 |
| PayMedix | Unknown | $25M | Jan 2023 |
| Health Payment Systems | Growth | $25M | Jan 2023 |
 Ria Health | Series A | $18M | Jun 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
 Quell Therapeutics | Series B | $156M | Nov 2021 |
Page 1 of 4
Top Co-Investors
Pfizer Ventures17 shared
RA Capital Management16 shared
M Ventures13 shared
Sofinnova Partners13 shared
Andera Partners11 shared
IP Group plc11 shared
Schroders Capital8 shared
Omega Funds8 shared
Dementia Discovery Fund8 shared
EQT Life Sciences7 shared
Arix Bioscience7 shared
Avidity Partners7 shared
The Invus Group, LLC7 shared
Alexandria Venture Investments7 shared
Eli Lilly and Company7 shared
Deep Track Capital6 shared
Samsara BioCapital6 shared
Novartis Pharma AG5 shared
Sanofi Ventures5 shared
Jeito Capital5 shared
Last updated: 9 September 2026